NO20030495L - Peptider som presenteres av celler - Google Patents

Peptider som presenteres av celler

Info

Publication number
NO20030495L
NO20030495L NO20030495A NO20030495A NO20030495L NO 20030495 L NO20030495 L NO 20030495L NO 20030495 A NO20030495 A NO 20030495A NO 20030495 A NO20030495 A NO 20030495A NO 20030495 L NO20030495 L NO 20030495L
Authority
NO
Norway
Prior art keywords
peptides
cells
determination
peptides presented
relates
Prior art date
Application number
NO20030495A
Other languages
English (en)
Other versions
NO20030495D0 (no
Inventor
Francis J Carr
Graham Carter
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20030495L publication Critical patent/NO20030495L/no
Publication of NO20030495D0 publication Critical patent/NO20030495D0/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20030495A 2000-08-03 2003-01-31 Peptider som presenteres av celler NO20030495D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (2)

Publication Number Publication Date
NO20030495L true NO20030495L (no) 2003-01-31
NO20030495D0 NO20030495D0 (no) 2003-01-31

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030495A NO20030495D0 (no) 2000-08-03 2003-01-31 Peptider som presenteres av celler

Country Status (20)

Country Link
US (1) US20030171290A1 (no)
EP (1) EP1305343B1 (no)
JP (1) JP2004506202A (no)
KR (1) KR20030037272A (no)
CN (1) CN1511164A (no)
AT (1) ATE306498T1 (no)
AU (1) AU2001283958A1 (no)
BR (1) BR0112925A (no)
CA (1) CA2417767A1 (no)
CZ (1) CZ2003464A3 (no)
DE (1) DE60114018T2 (no)
GB (1) GB0018901D0 (no)
HU (1) HUP0301581A2 (no)
MX (1) MXPA03000901A (no)
NO (1) NO20030495D0 (no)
PL (1) PL358874A1 (no)
RU (1) RU2003105806A (no)
SK (1) SK1982003A3 (no)
WO (1) WO2002012899A2 (no)
ZA (1) ZA200301637B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004513332A (ja) * 2000-09-18 2004-04-30 ジェンザイム、コーポレーション 質量分析法（ｍａｌｄｉ−ｔｏｆ）に基づいて抗体標的を同定するための方法
ATE386937T1 (de) * 2001-06-19 2008-03-15 Suntory Ltd Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
BRPI0415457A (pt) 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
MX2012005164A (es) 2009-11-05 2012-10-03 Cephalon Australia Pty Ltd Tratamiento de cancer que involucra genes kras o braf mutados.
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
KR102220382B1 (ko) * 2013-05-13 2021-02-25 셀렉티스 면역요법을 위한 매우 활성인 ｔ 세포를 조작하는 방법
RU2729116C2 (ru) 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
IL259023B (en) * 2016-09-30 2022-09-01 Cellex Life Sciences Incorporated Preparations containing protein-charged exosomes, methods for their production and uses thereof
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258817T3 (es) * 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
AU4676500A (en) * 1999-04-28 2000-11-10 Northwestern University Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
SK1982003A3 (en) 2003-08-05
ZA200301637B (en) 2004-02-03
BR0112925A (pt) 2003-08-26
HUP0301581A2 (hu) 2003-08-28
CA2417767A1 (en) 2002-02-14
CN1511164A (zh) 2004-07-07
DE60114018D1 (de) 2006-02-23
PL358874A1 (en) 2004-08-23
CZ2003464A3 (cs) 2003-06-18
ATE306498T1 (de) 2005-10-15
KR20030037272A (ko) 2003-05-12
NO20030495D0 (no) 2003-01-31
MXPA03000901A (es) 2003-06-24
DE60114018T2 (de) 2006-06-29
JP2004506202A (ja) 2004-02-26
WO2002012899A2 (en) 2002-02-14
AU2001283958A1 (en) 2002-02-18
EP1305343A2 (en) 2003-05-02
RU2003105806A (ru) 2004-07-20
EP1305343B1 (en) 2005-10-12
US20030171290A1 (en) 2003-09-11
GB0018901D0 (en) 2000-09-20
WO2002012899A3 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
NO20030495D0 (no) Peptider som presenteres av celler
EP2338333A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
ATE464067T1 (de) Bindegewebs wachstumsfaktor (ctgf)
DE60037450D1 (de) Funf-helix protein
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2002002783A3 (en) Expression vectors
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
WO2003106657A3 (en) NUCLEOTIDE SEQUENCES AND AMINO ACID SEQUENCES WISE / SOST
EP1801219A3 (en) Neisserial antigenic peptides
WO2004007547A3 (en) Truncated tau proteins
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
DE60313659D1 (de) Borrelidin-derivate und ihre medizinische anwendung
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO1999054349A3 (en) Dermatophagoides nucleic acid molecules, proteins and uses thereof
WO2004081033A3 (en) Synthesis of proteins by cell-free protein expression
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU8405798A (en) A swine hepatitis e virus and uses thereof
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2002102847A1 (fr) Nouveau ligand et son adn
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
WO2004050870A3 (en) Genetic switches for the detection of fusion proteins
WO1998051782A3 (en) Human 3-hydroxyisobutyryl-coenzyme a hydrolase